Immunological types of lymphoproliferative disorders in a cohort: a 4-year study.
Immunological testing of malignant cells and serum from most cases of lymphoproliferative disorders (LPD) allows the cell type to be characterised as of B, T or "null" lymphocyte origin. Regional differences in the incidence of neoplasms of these types have been reported. Furthermore, most published series have drawn cases from referral institutions rather than the general population. In order to determine the true incidence of a cohort we surveyed an entire population, that of Tasmania, an island state of Australia with a population of 410,000, during a defined period, the years 1977-1980 inclusive, for the occurrence of LPD. A total of 248 cases was discovered, made up of 133 cases of non-Hodgkin's lymphoma (NHL), 30 of chronic lymphocytic leukaemia (CLL), 18 of acute lymphoblastic leukaemia (ALL), 54 of multiple myeloma (MM), eight of macroglobulinaemia (MGA) and five others. We identified B lymphocytes by the presence of surface membrane immunoglobulin (Smlg) and their ability to rosette with mouse red blood cells, and T lymphocytes by their ability to rosette with sheep red blood cells. Laboratory testing was performed in 201 (81%) of the cases and characterisation of the cell of origin as of B, T or "null" type was successful in 158 (64%). Of these 158, 136 (86%) were B, 4 (3%) T, and 18 (11%) "null". On B cell subtyping by heavy and light chain lg analysis the Tasmanian series, compared with other reports, had an apparent paucity of B-CLL, MM and MGA of lambda subtype (57 k to 12 lambda, k:lambda ratio 4.8:1) and an unusual incidence of B-CLL with the double lg heavy chain combination M+G. Surveys of this type may help to point to environmental or other factors important in the aetiology of LPD.
D001315:Australia; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007945:Leukemia, Lymphoid / Q000453:epidemiology / Q000276:immunology; D008215:Lymphocytes, Null / Q000276:immunology*; D008223:Lymphoma / Q000453:epidemiology / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000276:immunology*; D009101:Multiple Myeloma / Q000453:epidemiology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D008258:Waldenstrom Macroglobulinemia / Q000453:epidemiology / Q000276:immunology